Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics, Incorporated (Nasdaq: CYTK) is a specialty cardiovascular biopharmaceutical company that regularly issues news about its medicines and programs in cardiac muscle dysfunction. Company updates frequently highlight MYQORZO (aficamten), a cardiac myosin inhibitor that Cytokinetics reports is approved in the United States and China for adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms, as well as related regulatory developments in other regions.
News for CYTK often covers key regulatory milestones such as positive opinions from the Committee for Medicinal Products for Human Use of the European Medicines Agency, approvals by national regulatory agencies and progress of New Drug Application reviews. Cytokinetics also reports on clinical trial data from studies like SEQUOIA-HCM and MAPLE-HCM, including results presented at major cardiology congresses and publications in peer-reviewed journals.
Investors and observers can find announcements about the company’s broader pipeline, including omecamtiv mecarbil in heart failure with severely reduced ejection fraction, ulacamten in heart failure with preserved ejection fraction and CK-089 in skeletal muscle disorders. Additional news items describe financial results, capital raising activities, inducement equity grants, executive appointments and participation in healthcare and investor conferences.
This CYTK news page aggregates these disclosures so readers can follow developments in Cytokinetics’ cardiovascular programs, regulatory interactions and corporate activities over time.
Cytokinetics (NASDAQ: CYTK) launched "On Track with HCM" on January 27, 2026, an awareness and support program focused on the whole-person impact of hypertrophic cardiomyopathy (HCM). The campaign features Olympic gold medalist Sydney McLaughlin-Levrone, her father Willie McLaughlin who lived with non-obstructive HCM before a heart transplant, and cardiologist Melissa Burroughs, MD. The program includes a dedicated website, OnTrackWithHCM.com, and eight original videos offering personal stories, clinical context, and practical guidance on fitness, nutrition, rest, social and family challenges for people living with HCM. The release reiterates that HCM affects up to 1 in 350 people and increases risk for atrial fibrillation, heart failure, and sudden cardiac arrest.
Cytokinetics (NASDAQ: CYTK) announced that MYQORZO (aficamten) is now available by prescription in the U.S. in 5 mg, 10 mg, 15 mg and 20 mg tablets following FDA approval on Dec 19, 2025.
MYQORZO is a once-daily oral cardiac myosin inhibitor indicated for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. The prescribing information includes a Boxed WARNING for heart failure risk; initiation is not recommended in patients with LVEF <55% and echocardiogram monitoring is required. MYQORZO is available only through a REMS program. Cytokinetics launched patient support services and specialty pharmacy distribution concurrent with availability.
Cytokinetics (Nasdaq: CYTK) announced inducement equity awards granted on January 15, 2026 to eight new employees hired in December 2025 and January 2026. The company granted options to purchase 29,416 shares and 19,825 restricted stock units (RSUs) that will settle in common stock upon vesting.
The RSUs vest over 3 years (40% at year 1, 40% at year 2, 20% at year 3). The options vest over 4 years (25% at year 1, then monthly over 36 months), carry a $63.44 exercise price (equal to the closing price on January 15, 2026) and have a 10-year term. Awards are subject to the company's equity plan and Nasdaq Listing Rule 5635(c)(4).
Cytokinetics (Nasdaq: CYTK) announced that Robert I. Blum, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 9:45 AM PT in San Francisco.
Investors can watch a live webcast via the company's Investors & Media website, and a replay will be archived on the website for 90 days after the event.
Cytokinetics (NASDAQ: CYTK) announced FDA approval of MYQORZO™ (aficamten) tablets (5 mg, 10 mg, 15 mg, 20 mg) for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.
The approval is based on SEQUOIA-HCM and includes a Boxed WARNING for risk of heart failure due to reduced LVEF, a REMS requirement, and echocardiogram monitoring recommendations. MYQORZO is expected to be available in the U.S. in the second half of January 2026. The company will host an investor call on Dec 19, 2025 at 4:30 PM ET.
Cytokinetics (NASDAQ: CYTK) announced NMPA approval of MYQORZO (aficamten) in China for adults with NYHA class II-III obstructive hypertrophic cardiomyopathy to improve exercise capacity and symptoms.
The approval triggers a $7.5 million milestone payment from Sanofi and leaves Cytokinetics eligible for up to $142.5 million additional development/commercial milestones plus royalties in the low-to-high teens on Greater China net sales. MYQORZO is currently approved only in China.
Regulatory progress noted: a U.S. NDA is under FDA review with a PDUFA date of December 26, 2025, and the EMA CHMP adopted a positive opinion on December 12, 2025, with a European Commission decision expected in Q1 2026.
Cytokinetics (Nasdaq: CYTK) announced inducement equity awards made on December 15, 2025 to 10 employees who began work in November–December 2025. The company granted 21,399 stock options and 14,422 restricted stock units (RSUs) to be settled in common stock.
The RSUs vest over 3 years (40%/40%/20% annual schedule). Options vest over 4 years (25% at one year, then monthly over 36 months), have a $62.16 exercise price (closing price on Dec 15, 2025) and a 10-year term. Awards follow Nasdaq Listing Rule 5635(c)(4).
Cytokinetics (Nasdaq: CYTK) announced a positive CHMP opinion recommending EU marketing authorization for MYQORZO (aficamten) to treat symptomatic (NYHA II-III) obstructive hypertrophic cardiomyopathy in adults.
A final European Commission decision is expected in Q1 2026. The CHMP opinion cites clinical evidence from the SEQUOIA-HCM trial. Aficamten is also under review by the FDA with a PDUFA date of Dec 26, 2025 and under Priority Review by China’s NMPA CDE.
Cytokinetics (Nasdaq: CYTK) announced inducement equity awards dated November 15, 2025 for new hires. The company granted options to purchase 87,297 RSUs (settled in shares) to Jeffrey Hessekiel, who began employment November 14, 2025, and granted options for an aggregate of 13,175 shares plus 8,881 RSUs to three additional employees who started in October–November 2025.
RSUs vest over 3 years (40%/40%/20%). Stock options have an exercise price of $66.44 (closing price on November 14, 2025), vest over 4 years with a one-year 1/4 cliff and monthly vesting thereafter, and a 10-year term. Awards were made under the 2004 Equity Incentive Plan in accordance with Nasdaq Rule 5635(c)(4).
Cytokinetics (Nasdaq: CYTK) announced on November 17, 2025 its support for a three-year American Heart Association initiative to improve diagnosis, access, and treatment for people living with hypertrophic cardiomyopathy (HCM).
The company said it will back efforts to expand participation in a national HCM Registry powered by Get With The Guidelines®, broaden certification for referring centers, introduce patient support services at key HCM centers, and pilot the Association’s HCM detection algorithm to reduce underdiagnosis.
The initiative targets systemic barriers to more consistent, equitable care for the estimated one in 500 U.S. people living with HCM.
FAQ
What is the current stock price of Cytokinetics (CYTK)?
What is the market cap of Cytokinetics (CYTK)?
